Ireland - English - HPRA (Health Products Regulatory Authority)

chiron vaccines limited - a/singapore686 - like strain (h1n1) a/wuhan /359/95 (h3n2)-like strain b/beijing /184/93-like strain - suspension for injection - %v/v

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis vaccines and diagnostics ltd - influenza virus surface antigens - suspension for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

chiron vaccines limited - a/singapore686 - like strain (h1n1) a/wuhan /359/95 (h3n2)-like strain b/beijing /184/93-like strain - suspension for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - panitumumab, quantity: 400 mg - injection, concentrated - excipient ingredients: sodium acetate trihydrate; sodium chloride; water for injections - vectibix is indicated for the treatment of patients with wild-type ras metastatic colorectal cancer (mcrc) (see precautions laboratory tests): - as first line therapy in combination with folfox. efficacy may be influenced by patient performance status (see clinical trials; precautions). - as second line therapy in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). efficacy may be influenced by patient performance status (see clinical trials). - as monotherapy in patients after the failure of standard chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - panitumumab, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium chloride; sodium acetate trihydrate; water for injections - vectibix is indicated for the treatment of patients with wild-type ras metastatic colorectal cancer (mcrc) (see precautions laboratory tests): - as first line therapy in combination with folfox. efficacy may be influenced by patient performance status (see clinical trials; precautions). - as second line therapy in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). efficacy may be influenced by patient performance status (see clinical trials). - as monotherapy in patients after the failure of standard chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - influenza virus haemagglutinin type a/bayern/7/95-like h1n1 15ug; influenza virus haemagglutinin type a/sydney/5/97-like h3n2 15ug; influenza virus haemagglutinin type b/beijing/184/93-like 15ug - suspension for injection - active: influenza virus haemagglutinin type a/bayern/7/95-like h1n1 15ug influenza virus haemagglutinin type a/sydney/5/97-like h3n2 15ug influenza virus haemagglutinin type b/beijing/184/93-like 15ug excipient: dibasic sodium phosphate monobasic potassium phosphate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 15ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 15ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza virus, types a and b in adults and children older than 6 months in accordance with the recommendations in the national immunisation guideline.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010); influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013); influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010) influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013) influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra is indicated in adults and children from 6 months of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - ranitidine hcl - injection - 25 mg/ml - ranitidine hcl 25 mg/ml